BPC-157 + TB-500
A two-peptide research blend examined through connective-tissue, vascular, and epithelial model systems.
View TB/BPC “WOLV” in the storeQuick answers
What is BPC-157 + TB-500?
BPC-157 + TB-500 is a two-peptide research blend examined through connective-tissue, vascular, and epithelial model systems. It is a blend of BPC-157 and TB-500 (N-acetylated heptapeptide fragment).
How much published research cites BPC-157 + TB-500?
The Luvaminos BPC-157 + TB-500 record cites 19 published references, dated 2003 to 2026. Each is listed on this page with a link to its source.
Does Luvaminos test BPC-157 + TB-500, and where is the certificate?
Yes. Every BPC-157 + TB-500 lot Luvaminos sells is tested by Freedom Diagnostics Testing, PLLC, an independent laboratory. The current 10 mg lot, WOLV-10-001, measured 99.40% purity by HPLC and a net content of BPC-157 5.72 mg + Thymosin Beta-4 4.72 mg, tested September 2, 2026. Its certificate is published at luvaminos.com/coa/WOLV-10-001.
How is BPC-157 + TB-500 powder stored?
Sealed BPC-157 + TB-500 powder: Keep sealed, dry, and protected from light; general synthetic-peptide handling guidance recommends storage at −20 °C or colder. Moisture, repeated freeze-thaw cycles, strong alkaline conditions, and light exposure can reduce integrity.
How is BPC-157 + TB-500 different from BPC-157?
BPC-157 is a single compound; BPC-157 + TB-500 is a blend of BPC-157 and TB-500 (N-acetylated heptapeptide fragment), with BPC-157 as one of its 2 components. BPC-157 has 15 amino acids and a molecular weight of 1,419.5 g/mol.
How is BPC-157 + TB-500 different from BPC-157 + TB-500 + GHK-Cu?
BPC-157 + TB-500 is a blend of BPC-157 and TB-500 (N-acetylated heptapeptide fragment); BPC-157 + TB-500 + GHK-Cu is a blend of GHK-Cu, TB-500 (Ac-LKKTETQ fragment) and BPC-157. BPC-157 + TB-500 + GHK-Cu adds GHK-Cu.
How is BPC-157 + TB-500 different from BPC-157 / TB-500 / KPV?
BPC-157 + TB-500 is a blend of BPC-157 and TB-500 (N-acetylated heptapeptide fragment); BPC-157 / TB-500 / KPV is a blend of BPC-157, TB-500 (full-length acetylated Thymosin Beta-4) and KPV. BPC-157 / TB-500 / KPV adds KPV.
Molecular Profile
- Type
- Peptide blend
Components
BPC-157
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1,419.5 g/mol
- CAS number
- 137525-51-0
- Sequence
- GEPPPGKPADDAGLV
TB-500 (N-acetylated heptapeptide fragment)
- Molecular formula
- C38H68N10O14
- Molecular weight
- 889.0 g/mol
- CAS number
- 885340-08-9
- Sequence
- Ac-LKKTETQ
Mechanism & Target Class
At the molecular level, this blend combines two structurally distinct peptides. BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) examined in indexed work using endothelial and fibroblast model systems, where readouts include tube-formation assays and phosphorylation measurements in cultured cells. TB-500 is characterized in peer-reviewed analytical work as an N-terminally acetylated heptapeptide, Ac-LKKTETQ, corresponding to a short actin-binding sequence motif within a larger endogenous peptide; related literature maps this sequence to actin-associated chemistry, cell-adhesion model systems, and migration-linked assays.
Storage & Handling
- Lyophilized
- Keep sealed, dry, and protected from light; general synthetic-peptide handling guidance recommends storage at −20 °C or colder.
- Handling
- moisture, repeated freeze-thaw cycles, strong alkaline conditions, and light exposure can reduce integrity.
Primary Database
References (19)
Reviews
1Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025). HSS Journal
- 2
McGuire FP, et al. (2025). Current Reviews in Musculoskeletal Medicine
- 3
Ying Y, Lin C, Tao N, Hoffman RD, Shi D, Chen Z, Gao J (2023). Current Protein & Peptide Science
- 4
Seiwerth S, Brcic L, Vuletic LB, et al. (2021). Frontiers in Pharmacology
- 5
Gwyer D, Wragg NM, Wilson SL (2019). Cell and Tissue Research
Primary research
6ClinicalTrials.gov (2026). ClinicalTrials.gov
- 7
ClinicalTrials.gov (2026). ClinicalTrials.gov
- 8
ClinicalTrials.gov (2020). ClinicalTrials.gov
- 9
ClinicalTrials.gov (2015). ClinicalTrials.gov
- 10
Rahaman KA, Muresan AR, Min H, Son J, Han H-S, Kang M-J, Kwon O-S (2024). Journal of Chromatography B
- 11
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JHS (2020). Scientific Reports
- 12
Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VHS, Pang JHS (2017). Journal of Molecular Medicine
- 13
Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS (2014). Molecules
- 14
Ho ENM, Kwok WH, Lau MY, Wong ASY, Wan TSM, Lam KKH, Schiff PJ, Stewart BD (2012). Journal of Chromatography A
- 15
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Drug Testing and Analysis
- 16
Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS (2011). Journal of Applied Physiology
- 17
Sosne G, Qiu P, Goldstein AL, Wheater M (2010). FASEB Journal
- 18
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK (2003). FASEB Journal
- 19
Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zoricic I, Klicek R, Radic B, Nikolic I, Juric G, Mester M, Petek M, Sikiric P (2003). Journal of Orthopaedic Research
Related compounds
Compared side by side